Business Context and Reporting Period
This Form 8-K was filed by Aziyo Biologics, Inc. (not Elutia Inc.) on November 19, 2020. The report serves to announce the Company's financial results for the quarter ended September 30, 2020. The Company is an emerging growth company incorporated in Delaware, with its Class A Common Stock trading on The Nasdaq Global Market under the symbol AZYO.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No material changes or comparative financial data are disclosed within the text of this filing. Investors must refer to the referenced press release (Exhibit 99.1) for a comparison against prior periods.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a detailed discussion of risks and contingencies. It functions solely as a notification that the Q3 2020 results have been issued via press release. The document includes a standard disclaimer that the information in the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 19, 2020), as they are absent from this summary document.
- Confirm the Company name is Aziyo Biologics, Inc. (Ticker: AZYO), noting the discrepancy with the "Elutia Inc." label in the request metadata.
- Review the full press release for any operational updates or clinical trial milestones that may accompany the financial results.
- Check subsequent filings for any restatements or updates to the Q3 2020 data.